Member Investor Portfolio Report
Q3 2024 Member Investor Portfolio Report
This quarter has seen continued momentum for Ohio’s leadership in this sector, with a surge in interest and investment from new and existing partners within and beyond Ohio. This issue showcases 16 life science companies that have achieved key milestones in areas such as venture funding, FDA approvals, partnerships, and product development.
Q2 2024 Member Investor Portfolio Report
New investors from outside Ohio continued to invest in innovative technologies throughout the state. This report also highlights 19 life science companies for their milestone achievements including fundraising, FDA approvals, clinical study completion, and business development expansion.
Q1 2024 Member Investor Portfolio Report
Despite economic challenges, out-of-state investment drove significant growth in Ohio’s life sciences sector in Q1 2024, with $271 million raised across 26 companies, notably in medical devices, therapeutics, and healthcare software. This first-of-its-kind report highlights the success and opportunity in Ohio’s rapidly growing life sciences sector.